» Articles » PMID: 19963361

COPD Health Care in Sweden - A Study in Primary and Secondary Care

Overview
Journal Respir Med
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2009 Dec 8
PMID 19963361
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To map out-patients with Chronic Obstructive Pulmonary Disease (COPD) with special reference to patients suffering from acute exacerbations, and to describe COPD health care structure and process in Swedish clinical practice in a real life setting.

Design: Retrospective, non-interventional, epidemiological survey.

Setting: 141 hospital based out patient clinics (OPC, n=30) and primary health care clinics (PC, n=111) were included in the structure evaluation.

Subjects: 1004 COPD diagnosed patients from 100 of the centres (OPC, n=26) participated in the process evaluation.

Methods: All Swedish OPC (n=40) and a random sample of 180 PC were asked to answer a questionnaire regarding COPD care. In addition, data from 10 randomly selected patients with a documented COPD disease were analysed from the centres.

Results: Spirometers were available at all OPCs and at 99% of the PCs. Spirometry had been performed in 52% of PC-patients and in 89% of OPC-patients during the last 2 years prior to the study. More severe patients, as judged by investigator and lung function data, were treated at OPCs than at PCs. Physiotherapists, occupational therapists and dieticians were available at >80% of centres. Exacerbation rate was higher at PCs without a specialized nurse, 2.2/year versus 0.9/year at centres with a specialized nurse.

Conclusions: Special attention to COPD, marked by a specialised nurse in primary care improves the quality, as assessed by a lower number of exacerbations. The structure of COPD care in Sweden for diagnosed individuals seems satisfactory, but could be improved mainly through higher availability and educational activities.

Citing Articles

Remote monitoring of patients with COPD disease using a tablet system: a randomised crossover study of quality-of-life measurements.

Frerichs M, Li H, Andersson A, Andelid K, Crona M, Vanfleteren L ERJ Open Res. 2025; 11(1.

PMID: 39811558 PMC: 11726541. DOI: 10.1183/23120541.00532-2024.


Evaluation of the Effectiveness of Additional Risk Minimisation Measures for Tofacitinib (Xeljanz) in Europe: A Prescriber Survey.

Wu J, Koram N, Asomaning K, Merchant L, Massouh R, Nagy E Clin Drug Investig. 2024; 44(12):961-974.

PMID: 39609366 PMC: 11638417. DOI: 10.1007/s40261-024-01408-5.


COPD - do the right thing.

Sandelowsky H, Weinreich U, Aarli B, Sundh J, Hoines K, Stratelis G BMC Fam Pract. 2021; 22(1):244.

PMID: 34895164 PMC: 8666021. DOI: 10.1186/s12875-021-01583-w.


Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study.

Hoogendoorn M, Corro Ramos I, Soulard S, Cook J, Soini E, Paulsson E BMJ Open. 2021; 11(8):e049675.

PMID: 34348953 PMC: 8340281. DOI: 10.1136/bmjopen-2021-049675.


Reply to: "Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies" [Letter].

Barnes N, Singh D, Lipson D Int J Chron Obstruct Pulmon Dis. 2021; 16:1299-1301.

PMID: 34007169 PMC: 8121158. DOI: 10.2147/COPD.S304368.